J&J’s Skin Drug Beats Humira in Final-Stage Psoriasis Study
- Drugmaker positioning itself to expand immune treatments
- Guselkumab targets protein involved in skin immune response
This article is for subscribers only.
Johnson & Johnson’s experimental drug for psoriasis hit its main goals and outperformed a rival in a final-stage study, positioning the company to expand its arsenal of immune-disease treatments.
The drug, called guselkumab, cleared or nearly cleared the skin of 81 percent of patients after 48 weeks of treatment, the company said Saturday in a summary of research findings. That compared with a 55 percent rate among those on AbbVie Inc.’s Humira, New Brunswick, New Jersey-based J&J said.